• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4625217)   Today's Articles (2472)   Subscriber (49494)
For: Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010;6:113-33. [PMID: 20448797 PMCID: PMC2860444 DOI: 10.2147/vhrm.s7857] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Indexed: 12/21/2022]  Open
Number Cited by Other Article(s)
1
Sah SK, Alam K, Kumari M, Malootty R, Nath S, Ravichandiran V, Roy S, Kaity S. A 3D in-vitro biomimicking Caco-2 intestinal permeability model-based assessment of physically modified telmisartan towards an alkalizer-free formulation development. Eur J Pharm Biopharm 2024;203:114480. [PMID: 39222674 DOI: 10.1016/j.ejpb.2024.114480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Revised: 08/26/2024] [Accepted: 08/30/2024] [Indexed: 09/04/2024]
2
Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother 2024;171:116169. [PMID: 38228033 DOI: 10.1016/j.biopha.2024.116169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Revised: 01/04/2024] [Accepted: 01/11/2024] [Indexed: 01/18/2024]  Open
3
Lee DH, Kim MT, Lee HW, Han JH, Myung CS. The combined effects of telmisartan and ramipril on hypertension and cardiovascular injury. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2022. [DOI: 10.1007/s40005-022-00567-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
4
Liu CH, Sung PS, Li YR, Huang WK, Lee TW, Huang CC, Lee TH, Chen TH, Wei YC. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med 2021;18:e1003707. [PMID: 34280191 PMCID: PMC8289120 DOI: 10.1371/journal.pmed.1003707] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 06/22/2021] [Indexed: 11/21/2022]  Open
5
Jo JH, Lee DH, Han JH, Lee M, Jang KW, Myung CS. Effects of combination treatment with cilnidipine and telmisartan on hypertension, cardiovascular injury, and high blood glucose. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2021. [DOI: 10.1007/s40005-021-00522-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
6
Hot-Melt Extruded Amorphous Solid Dispersion for Solubility, Stability, and Bioavailability Enhancement of Telmisartan. Pharmaceuticals (Basel) 2021;14:ph14010073. [PMID: 33477557 PMCID: PMC7831136 DOI: 10.3390/ph14010073] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 01/14/2021] [Indexed: 12/22/2022]  Open
7
Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF. Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity. Diabetes Metab Syndr Obes 2020;13:3627-3635. [PMID: 33116714 PMCID: PMC7567533 DOI: 10.2147/dmso.s265399] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 09/10/2020] [Indexed: 12/19/2022]  Open
8
Wang J, Liu J, Song X, Fu C. Simultaneous Determination of Telmisartan and Pitavastatin Calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study. Pharm Nanotechnol 2020;8:313-322. [PMID: 32515316 DOI: 10.2174/2211738508666200607181727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 04/09/2020] [Accepted: 04/22/2020] [Indexed: 02/08/2023]
9
Ostroumova OD, Kochetkov AI, Ageev FT, Anikin GS, Akhmetzyanova EK, Bezuglova EI, Bekoeva AB, Borovkova NY, Vinogradova NG, Gorbunova EV, Goryacheva AA, Zhugrova ES, Kislyak OA, Klyashev SM, Kuzmin VP, Lipchenko AA, Matyushin GV, Mikhailova EA, Nevzorova VA, Obrezan AG, Petrichko TA, Petrova MM, Reider AN, Repin AN, Sadovoy VI, Sanina NP, Skripchenko AE, Stryuk RI, Faiyance IV, Khaisheva LA, Khasanov NR, Khokhlov RA, Tsareva EE, Cherkashina AL, Shaposhnik II, Shelestova IA, Shepel RN, Shikh EV, Yakhontov DA. The Effects of Telmisartan and Its Combinations on Office Blood Pressure: Results of Prospective Observational Study TAINA. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY 2020. [DOI: 10.20996/1819-6446-2020-04-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]  Open
10
Sayutina EV, Butorova LI, Tuaeva EM, Osadchuk MA. Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2020. [DOI: 10.15829/1728-8800-2020-1-106-117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]  Open
11
Sayutina EV, Butorova LI, Tuaeva EM, Osadchuk MA. Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2020. [DOI: 10.15829/1728-8800-2020-1-2453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]  Open
12
Zhao D, Liu H, Dong P. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clin Exp Hypertens 2018;41:75-79. [PMID: 29589977 DOI: 10.1080/10641963.2018.1445750] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
13
Lee AR, Kwon SY, Choi DH, Park ES. Quality by Design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduo®) manufactured via high shear wet granulation. Int J Pharm 2017;534:144-158. [PMID: 29031980 DOI: 10.1016/j.ijpharm.2017.10.004] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 09/17/2017] [Accepted: 10/01/2017] [Indexed: 02/08/2023]
14
Efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low-dose combination therapy. Int J Hypertens 2014;2014:475480. [PMID: 24719757 PMCID: PMC3955615 DOI: 10.1155/2014/475480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 01/15/2014] [Indexed: 01/13/2023]  Open
15
Kjeldsen S, Mancia G, Schmieder R, Mattheus M, Unger T. An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Rev Cardiovasc Ther 2013;11:673-82. [PMID: 23750676 DOI: 10.1586/erc.13.63] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
16
Düsing R, Brunel P, Baek I, Baschiera F. Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose. J Clin Hypertens (Greenwich) 2013;15:41-7. [PMID: 23282123 PMCID: PMC8108266 DOI: 10.1111/jch.12018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Revised: 08/10/2012] [Accepted: 08/15/2012] [Indexed: 11/30/2022]
17
Cha JH, Lee HR, Kim KC, Cho MS, Hong YM. Changes of gene expressions in spontaneously hypertensive rat model after losartan treatment. Korean Circ J 2012;42:761-8. [PMID: 23236328 PMCID: PMC3518710 DOI: 10.4070/kcj.2012.42.11.761] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2012] [Revised: 03/31/2012] [Accepted: 06/04/2012] [Indexed: 11/12/2022]  Open
18
Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. Nucl Med Biol 2012;39:1232-5. [DOI: 10.1016/j.nucmedbio.2012.06.012] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2012] [Revised: 06/18/2012] [Accepted: 06/19/2012] [Indexed: 11/21/2022]
19
Ruilope LM, Schumacher H. Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension. Expert Opin Pharmacother 2012;13:2417-25. [PMID: 23051558 DOI: 10.1517/14656566.2012.733698] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
20
Shimizu Y, Yamasaki F, Furuno T, Kubo T, Sato T, Doi Y, Sugiura T. Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension. Int J Gen Med 2012;5:753-8. [PMID: 23049268 PMCID: PMC3459667 DOI: 10.2147/ijgm.s28890] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
21
Galzerano D, Di Michele S, Paolisso G, Tuccillo B, Lama D, Carbotta S, Cittadini A, Tedesco MA, Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012;13:496-503. [DOI: 10.1177/1470320312443909] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
22
Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol 2012;11:32. [PMID: 22490507 PMCID: PMC3351968 DOI: 10.1186/1475-2840-11-32] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2011] [Accepted: 04/10/2012] [Indexed: 01/13/2023]  Open
23
Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, Galli E. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother 2012;12:2719-35. [PMID: 22077832 DOI: 10.1517/14656566.2011.632367] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
24
Maladkar M, Verma VK, Narsikar KA, Walinjkar RD, Patil WR, Saggu NJS, Kulkarni SP. Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension. ACTA ACUST UNITED AC 2012. [DOI: 10.4236/ojim.2012.22014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
25
Frampton JE. Telmisartan. Drugs 2011;71:651-77. [DOI: 10.2165/11206710-000000000-00000] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
26
J A. Improving hypertension control in patients at cardiovascular risk: the case for telmisartan-based therapy. Cardiovasc J Afr 2011;22:45-6. [PMID: 21298207 PMCID: PMC6053648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]  Open
27
Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, Gao PJ, Huang DY, Shuster M, Loibner H, Guo JM, Yu XY, Xiao BX, Gong ZH, Penninger JM, Oudit GY. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. ACTA ACUST UNITED AC 2011;166:90-7. [DOI: 10.1016/j.regpep.2010.09.005] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2010] [Revised: 08/26/2010] [Accepted: 09/13/2010] [Indexed: 12/21/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA